Skip to main content

NuCana plc

corporate_fare Company Profile

NuCana plc

NCNA·NASDAQ·Life Sciences·CIK 0001709626

NuCana plc is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes. The company applies its ProTide technology to transform widely prescribed chemotherapy agents, known as nucleoside analogs, into more effective and safer medicines. This technology also enables the therapeutic development of nucleosides that have previously failed due to resistance mechanisms and metabolic limitations. While conventional nucleoside analogs are standard treatments for many solid and hematological tumors, they have significant shortcomings that limit their efficacy and are often poorly tolerated. NuCana's proprietary ProTide technology is designed to overcome these limitations by generating much higher concentrations of anti-cancer metabolites within cancer cells. The company was incorporated in England and Wales in 1997 as Biomed (UK) Limited, commenced operations in 2008, and changed its name to NuCana BioMed Limited on April 28, 2008. On August 29, 2017, it re-registered as a public limited company and became NuCana plc. On October 2, 2017, the company completed its initial public offering of American Depositary Shares (ADSs) on The Nasdaq Global Select Market. On November 9, 2023, the listing was transferred to The Nasdaq Capital Market, where its ADSs trade under the symbol "NCNA".

NuCana plc (NASDAQ:NCNA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 8 items for NCNA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-13, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for NCNA spans 6-K, 20-F, SCHEDULE 13D.

Recent high-impact activity:

  • NuCana Q2 Loss Narrows to £3.1M; Cash Runway Extended into 2029
  • Shareholders Approve Resolutions for Future Capital Raises
  • NuCana Reports Q1 2026 Results, Secures FDA IND for NUC-7738, Extends Cash Runway into 2029
  • NuCana plc Seeks Share Subdivision and Highly Dilutive Share Issuance Authority for Critical Financing
  • NuCana plc Extends Cash Runway into 2029 via Significant Capital Raises and Reports Mixed Clinical Progress

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$29.35M
Diluted EPS
$0.00
Op. Cash Flow
-$7.47M
Free Cash Flow
-$7.47M
Operating Income
-$20.11M
Cash & Equivalents
$24.25M
Debt / Equity
0.00×
Shares Outstanding
35.85B sh
Source: 20-F · filed 2026-03-19 · accession 0001193125-26-116030

Short Interest & Short Volume

4.88 days to cover

FINRA reported short interest of 139,251 shares in NCNA as of the October 30, 2026 settlement, a 4.0% decrease from the prior period — about 4.9 days to cover at its recent average daily volume. On November 20, 2026, 22.6% of NCNA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)139,251 shares as of October 30, 2026
Change vs prior period▼ 4.0%
Days to cover4.88 at avg daily volume of 28,561
Daily short volume (FINRA facilities)22.6% of 13,416 shares on November 20, 2026
5-day average short volume28.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

NCNA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with N →
$0.7221 -3.66% today
52-week range · as of 2026-08-13 $0.7221 – $7.22
Market cap
$3.61M
Volume
25.5K (0.8× avg)
3-mo avg 31.6K
Live data · 2026-11-22 11:23 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NCNA - Latest Insights

NCNA
Aug 13, 2026, 4:17 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.48
Real-time Price: $0.7221 info
Change: -$0.7579 (-51%) info
Market Cap: $3.61M info
NCNA
Jun 08, 2026, 7:52 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.04
Real-time Price: $0.7221 info
Change: -$1.32 (-65%) info
Market Cap: $3.61M info
NCNA
May 14, 2026, 4:44 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.93
Real-time Price: $0.7221 info
Change: -$1.21 (-63%) info
Market Cap: $3.61M info
NCNA
May 06, 2026, 4:07 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.21
Real-time Price: $0.7221 info
Change: -$1.49 (-67%) info
Market Cap: $3.61M info
NCNA
Mar 19, 2026, 4:23 PM EDT
Filing Type: 20-F
Importance Score:
8
Price at Filing: $1.75
Real-time Price: $0.7221 info
Change: -$1.03 (-59%) info
Market Cap: $3.61M info
NCNA
Mar 19, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.77
Real-time Price: $0.7221 info
Change: -$1.05 (-59%) info
Market Cap: $3.61M info
NCNA
Mar 18, 2026, 6:39 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $0.7221 info
Change: -$1.02 (-59%) info
Market Cap: $3.61M info
NCNA
Jan 06, 2026, 8:12 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.65
Real-time Price: $0.7221 info
Change: -$2.93 (-80%) info
Market Cap: $3.61M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets